Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications.

Abstract

These data clearly demonstrate that the transcriptional control afforded by the cox-2 promoter is tumor-specific and is able to mitigate associated toxicity in normal tissue while maintaining therapeutic efficacy in the context of an ovarian cancer molecular chemotherapeutic approach.